BioSpace News Archive

Bold Therapeutics presented positive Phase 2 safety and efficacy data in advanced metastatic colorectal cancer (mCRC) patients treated with BOLD-100 in combination with FOLFOX previously treated with FOLFOX/CAPOX at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on January 18-20, 2024.

Pi-Cardia Ltd. announced today it received Breakthrough Device Designation from the US Food and Drug Administration for ShortCut™ - the world’s first dedicated leaflet modification device facilitating valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures in patients at risk of coronary obstruction.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce the Company has closed a non-brokered private placement (the “Offering”) of unsecured convertible debentures (each, a “Debenture”).

BioUtah, Utah’s trade association dedicated to the life sciences community, in partnership with the University of Utah’s Technology Licensing Office, today announced a venue change and speaker update for the 2024 Entrepreneur and Investor Life Sciences (E&I Summit) sponsored by Wilson Sonsini.

The American Society for Transplantation and Cellular Therapy (ASTCT), the Association of American Cancer Institutes (AACI), and the Association of Community Cancer Centers (ACCC) recently announced the RECUR initiative.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share (or per common stock equivalent) and accompanying warrants.

Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28% in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) vs. sunitinib after eight years, regardless of International Metastatic RCC Database Consortium (IMDC) risk group.

Gannex Pharma Company Ltd, a wholly-owned company of Ascletis Pharma Inc., announced that its strategic partner, Sagimet Biosciences Inc., reported positive topline results from Sagimet’s FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis at week 52.

Texas Children’s Hospital announces that Biological E’s CORBEVAX®, a traditional, recombinant protein-based COVID-19 vaccine has received World Health Organization approval under Emergency Use Listing.

Avidity Biosciences, Inc. announced that on January 20, 2024, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,650 shares of its common stock and 18,825 restricted stock units to four new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.